News | Chiesi Farmaceutici S.p.A.

Home > News

Chiesi Announces Discontinuation of the Tanimilast Program

Chiesi Group today announced its decision to conclude all clinical trials for the tanimilast program in Chronic Obstructive Pulmonary Disease (COPD) and asthma. This decision follows the full...

Chiesi Announces Results of the Tanimilast Phase III PILASTER Clinical Study in Chronic...

ISO 37001:2016 Certification: Chiesi Farmaceutici Starts the Extension Process of the Certification...

ARCHIVE NEWS

LEED Certification: Sustainable Workspaces for People and the Planet

12 March 2025

In Memory of Dr. Paolo Chiesi: Visionary Leader and Innovator

05 March 2025

Embracing Sustainability and Inclusivity: Updated Code of Interdependence

24 February 2025

Chiesi Group Reaffirms Its EcoVadis Platinum Medal

13 December 2024

Chiesi Group’s near and long-term science-based emissions reduction targets have been validated by the SBTi

25 October 2024

Code of Interdependence Workshop: a great opportunity for collaboration

25 September 2024

Chiesi to Present Data at the American Thoracic Society Conference

17 May 2024

Empowering Diversity & Inclusion: Chiesi Affinity Networks

10 May 2024

Chiesi Farmaceutici S.p.A. has obtained ISO 37001:2016 certification for its Anti-Bribery Management System

02 May 2024

Chiesi Achieves Platinum Medal from EcoVadis

12 March 2024

1 2 3 4 5 6 7 8 9 10 >>

© 2025 CHIESI Farmaceutici S.p.A.

VAT IT 01513360345
Company's Capital: Euro 75.000.000
Companies Register Office - Parma N.15739
REA: 159271

PHARMACOVIGILANCE

TO REPORT ADVERSE DRUG EVENTS/REACTIONS PLEASE CLICK HERE

follow us on: